Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Measurable Residual Disease (MRD) Focus

Understanding Clinical Endpoints In Measurable Residual Disease

The MRD Focus on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company). This supporter has no influence over the production of the content.

Welcome to Measurable Residual Disease (MRD) Focus

Explore the cutting-edge updates in MRD by disease type, including expert interviews from major international congresses, podcasts and e-learning.

MRD is the term used to describe a small number of cancer cells remaining in patients following treatment, which are below the level of routine morphological detection. Even when a patient is in remission it is possible for them to be ‘MRD positive’. The level of MRD can, theoretically, be used as a prognostic indicator to determine treatment efficacy and to detect cancer recurrence. MRD status is now increasingly measured as an endpoint in clinical trials for haematological malignancies, with the goal of treatment being MRD negativity.

Videos by Disease

Multiple Myeloma
CLL
Lymphoma
AML
ALL
MDS

Videos by Congress

ASH 2023
iwCLL 2023
IMS 2023
SOHO 2023
ICML 2023
EHA 2023